Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been featured in a NetworkNewsAudio editorial highlighting the company's innovative approach to treating multiple sclerosis (MS). The audio press release, titled “Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis”, accompanies a previously published editorial that underscores the growing demand for therapies that go beyond symptom management. The global MS therapeutics market is projected to reach $38.62 billion by 2030, reflecting the urgent need for disease-modifying treatments.
The feature focuses on Quantum BioPharma's lead candidate, Lucid-MS, a patented, first-in-class drug candidate designed to target the myelin sheath directly. The company aims to prevent, stop, and potentially reverse myelin degradation, which is the underlying mechanism of multiple sclerosis. Currently, many MS treatments only manage symptoms or slow progression, leaving a significant gap for therapies that can alter the disease course. Lucid-MS seeks to fill that gap by addressing the root cause of neurodegeneration in MS.
Multiple sclerosis is a chronic autoimmune disorder that affects the central nervous system, leading to demyelination—damage to the protective myelin sheath surrounding nerve fibers. This damage disrupts nerve signal transmission, causing a range of symptoms from fatigue and mobility issues to cognitive decline. The MS therapeutics market has seen growth in recent years, but the majority of approved drugs are immunomodulators that reduce inflammation or modulate the immune system. Few directly promote remyelination or repair. Quantum BioPharma's Lucid-MS represents a potential paradigm shift by focusing on myelin repair and protection.
The company stated that Lucid-MS has shown the ability to prevent and reverse myelin degradation in preclinical models. If these results translate to human trials, Lucid-MS could become a cornerstone therapy for MS patients. The drug candidate is being developed through Quantum's wholly owned subsidiary, Lucid Psycheceuticals Inc. Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders.
In addition to Lucid-MS, Quantum has developed UNBUZZD(TM), a product for alcohol misuse, and spun out its over-the-counter version to Unbuzzd Wellness Inc. Quantum retains a 19.84% ownership stake in Unbuzzd and is entitled to royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. The company also retains 100% rights to develop similar products for pharmaceutical and medical uses.
The editorial highlights the massive unmet need in MS, where approximately 2.8 million people worldwide are affected. Current therapies often have limited efficacy or significant side effects, driving demand for innovative treatments. Quantum BioPharma's approach with Lucid-MS could potentially offer a new therapeutic option that not only halts disease progression but also reverses damage, improving quality of life for patients. The company's inclusion in NetworkNewsAudio's feature signals growing interest in its pipeline and the potential impact on the MS treatment landscape.
